HTX-011 + Bupivacaine Hydrochloride + Ibuprofen + Acetaminophen
ApprovedCompleted 0 views this week 0 watching💤 Quiet
Interest: 33/100
33
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Postoperative Pain
Conditions
Postoperative Pain, Total Shoulder Arthroplasty, Multimodal Analgesia
Trial Timeline
Oct 20, 2021 → Jul 29, 2022
NCT ID
NCT06109415About HTX-011 + Bupivacaine Hydrochloride + Ibuprofen + Acetaminophen
HTX-011 + Bupivacaine Hydrochloride + Ibuprofen + Acetaminophen is a approved stage product being developed by Heron Therapeutics for Postoperative Pain. The current trial status is completed. This product is registered under clinical trial identifier NCT06109415. Target conditions include Postoperative Pain, Total Shoulder Arthroplasty, Multimodal Analgesia.
What happened to similar drugs?
20 of 20 similar drugs in Postoperative Pain were approved
Approved (20) Terminated (3) Active (0)
Hype Score Breakdown
Clinical
20
Activity
8
Company
5
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06109415 | Approved | Completed |
| NCT06109428 | Approved | Completed |
Competing Products
20 competing products in Postoperative Pain